Its Not Recommended by Either the FDA or the Drug Maker Both the US Food and Drug Administration (FDA) and Novo Nordisk, the maker of Wegovy and Ozempic, have warned against splitting semaglutide doses exactly for the reasons weve outlined above: its not sterile, it introduces too much room for error, and it can increase the risk of side effects
1,2 The latest standards of care from the American Diabetes Association (ADA), and the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE), highlight in particular the important influence of comorbid cardiovascular disease (CVD), chronic kidney disease (CKD), and heart failure (HF) on treatment selection
To help you understand what to expect, weve created this week-by-week guide to potential side effects of Ozempic
He provides clinical guidance on patient safety, treatment planning, and evidence-based protocols across a broad range of services, including injectables, skin health, and medical weight management